AX-2024-004882 · GHRP-6 · ERP lot ERP-2408-R9378

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	99.00	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.00	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — oxidised Trp (+16 Da)	0.69	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	872.4446	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	872.4256	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-21.8	ppm	± 15	FAIL
Total peptide content	by difference from the gravimetric mass balance	89.54	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	88.64	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	2.27	mg	2 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	2.012	mg	2 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	100.6	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.64	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.32	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.50	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.78	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	7.10	min	7.15 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.04	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	68,429	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.90	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 68,429, and skew follows the reported asymmetry factor of 1.04. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.69 % impurity against a 99.00 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-6 — main peak	7.10	4,811,707	99.00	—
2	oxidised Trp (+16 Da)	6.82	33,536	0.69	+15.995
3	[D-Trp]-epimer	7.00	7,290	0.15	0.000
4	bis-oxidised Trp (+32 Da)	6.62	4,374	0.09	+31.990
5	des-Lys (−128 Da)	6.92	3,402	0.07	-128.095
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 872.4446 Da, computed from C46H56N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 872.4256 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	437.2296	437.2201	-0.0095	50.6
1+	873.4519	873.4329	-0.0190	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.64
Counter-ion (acetate)	ion chromatography	5.32
Residual solvent + inorganic residue	estimated	0.50
Total peptide content	by difference	89.54
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.0	99.00	divergence +0.17 pp vs batch median
Total impurities (% area)	not stated	1.00
Largest single impurity (% area)	not stated	0.69
Water (%)	4.2	4.64
Counter-ion (%)	not stated	5.32
Peptide content (%w/w)	91.0	89.54
Endotoxin (EU/mg)	0.79	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 7 d) → laboratory (courier, dry ice, 12 d) → assay.
Assay date: 15 Aug 2024
Submitted to the index: 26 Aug 2024
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 5

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

ppm_error26 Aug 2024

Worth noting the sign. Calibration drift is usually one-directional across a sequence, so an excursion in the same direction as the laboratory's recent mean is a drift and one against it is something else.

coa_reader26 Aug 2024

What resolves this in one email is the batch record rather than the summary sheet: the integration report at full precision, with the reporting threshold stated. It is routinely available.

coa_template26 Aug 2024

The index publishes the declared figure and the measured figure side by side and does not adjudicate between them. Both are on this page and the difference is stated rather than characterised.

buyer_sourced26 Aug 2024

Ordering under an unremarkable name and address is the whole method. It requires no cooperation from anybody and it produces the strongest evidence this index holds.

same_trace_twice26 Aug 2024

Noted. Logged against the batch rollup.

Section 7

Related records

Same batch — lot ERP-2408-R9378 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2024-004881	ERP-2408-R9378	Janoshik	2024-Q3	98.64	5.42	90.8	Buyer-sourced	1	FAIL
AX-2024-004883	ERP-2408-R9378	Janoshik	2024-Q3	98.54	4.94	—	Buyer-sourced	1	FAIL
AX-2024-004884	ERP-2408-R9378	PeptideMeter	2024-Q3	98.90	5.15	93.5	Buyer-sourced	2	FAIL
AX-2024-004885	ERP-2408-R9378	PeptideMeter	2024-Q3	98.94	5.39	101.8	Buyer-sourced	1	FAIL
AX-2024-004886	ERP-2408-R9378	Janoshik	2024-Q3	98.83	4.81	98.3	Buyer-sourced	1	FAIL
AX-2024-004887	ERP-2408-R9378	Medutest	2024-Q3	99.37	4.81	—	Supplier-supplied	1	MARGINAL
AX-2024-004888	ERP-2408-R9378	Janoshik	2024-Q3	98.71	4.88	96.3	Buyer-sourced	1	FAIL
AX-2024-004889	ERP-2408-R9378	Janoshik	2024-Q3	98.51	4.81	103.2	Buyer-sourced	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-6 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042012	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-042528	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	98.69	1.87	95.8	Buyer-sourced	0	FAIL
AX-2026-042015	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS
AX-2026-042526	HJ	HJ-2603-R5329	Medutest	2026-Q3	99.37	3.06	—	Laboratory-retained	0	PASS
AX-2026-042527	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	99.21	2.77	93.2	Buyer-sourced	0	PASS
AX-2026-042525	HJ	HJ-2603-R5329	Janoshik	2026-Q3	99.52	3.24	92.0	Buyer-sourced	0	PASS
AX-2026-042013	AMB	AMB-2603-S5667	Kestrel	2026-Q3	99.93	5.75	—	Buyer-sourced	0	PASS
AX-2026-042017	AMB	AMB-2603-S5667	Medutest	2026-Q3	99.76	6.42	97.4	Buyer-sourced	0	PASS

Other recent ERP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042706	Survodutide	ERP-2605-E9865	PeptideMeter	2026-Q3	98.38	5.33	103.5	Buyer-sourced	0	PASS
AX-2026-042704	Tesamorelin	ERP-2604-W9463	Janoshik	2026-Q3	99.02	4.08	—	Buyer-sourced	1	MARGINAL
AX-2026-042705	Survodutide	ERP-2605-E9865	Janoshik	2026-Q3	98.24	5.36	92.3	Buyer-sourced	0	PASS
AX-2026-042708	GHK-Cu	ERP-2601-F9816	Nordanalyt	2026-Q2	98.88	3.87	91.5	Buyer-sourced	1	MARGINAL
AX-2026-042694	Liraglutide	ERP-2601-P8985	Kestrel	2026-Q2	99.25	4.35	107.3	Buyer-sourced	1	MARGINAL
AX-2026-042707	GHK-Cu	ERP-2601-F9816	Janoshik	2026-Q2	98.53	4.70	96.3	Buyer-sourced	1	MARGINAL
AX-2026-042711	GHK-Cu	ERP-2601-F9816	Kestrel	2026-Q2	98.53	3.84	89.7	Laboratory-retained	2	MARGINAL
AX-2026-042722	Tirzepatide	ERP-2512-T9616	Medutest	2026-Q2	99.18	2.07	—	Buyer-sourced	1	MARGINAL